UK Markets closed

Vifor Pharma AG (GNHAY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
26.75+0.08 (+0.30%)
At close: 10:55AM EST
Full screen
Trade prices are not sourced from all markets
Previous close26.67
BidN/A x N/A
AskN/A x N/A
Day's range26.75 - 26.75
52-week range25.50 - 32.10
Avg. volume71
Market cap8.674B
Beta (5Y monthly)1.30
PE ratio (TTM)22.23
Earnings dateN/A
Forward dividend & yield0.44 (1.65%)
Ex-dividend date10 May 2021
1y target estN/A
  • Reuters

    Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - report

    After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian. Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation. Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.

  • Motley Fool

    ChemoCentryx, inc (CCXI) Q3 2021 Earnings Call Transcript

    CCXI earnings call for the period ending September 30, 2021.

  • Motley Fool

    Cara Therapeutics, inc (CARA) Q3 2021 Earnings Call Transcript

    Please be advised that this call is being recorded at Cara's request. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' third quarter 2021 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.